T, has transformed treatment for blood cancers. The immunotherapy involves reprogramming a patient's own immune cells to ...

Researchers screening roughly 400 transcription factors found that disabling a single protein, NFIL3, allowed CAR T-cells to ...

Pooled Phase 1/2 data show 80% complete remission rate in pediatric R/R T-ALL/LBL patientsGlobal TENACITY-01 study reports 86% overall response ...

Patients with T-cell acute lymphoblastic leukaemia (T-ALL) and the closely related peripheral T-cell lymphoblastic lymphoma ...

Issued on behalf of GT Biopharma, Inc.Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash ...

Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare.

A pioneering clinical trial has successfully enabled two patients with end-stage kidney disease to receive previously ...

Three patients with recurrent glioblastoma, the most lethal primary brain cancer, experienced rapid and dramatic tumor ...

Early data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca’s ...

Broad-spectrum antibiotic use before and after CAR T correlates with worse overall survival and increased neurotoxicity, although confounding exists because antibiotics cluster with cytokine release ...

Chimeric antigen receptor (CAR)-T cells are a promising cancer therapy that are made from the patient's own T cells, which are reprogrammed to fight their cancer. One of the limitations of CAR-T cell ...

Diffuse intrinsic pontine glioma (DIPG) is one of the most devastating pediatric brain tumors. It sits in the brainstem where it cannot be surgically removed, responds poorly to chemotherapy, and ...